Oragenics Inc. Common Stock (OGEN)
0.1200
-0.0124 (-9.37%)
NYSE · Last Trade: May 31st, 7:56 PM EDT
Detailed Quote
| Previous Close | 0.1324 |
|---|---|
| Open | 0.1370 |
| Bid | 0.1171 |
| Ask | 0.1200 |
| Day's Range | 0.1100 - 0.1370 |
| 52 Week Range | 0.1617 - 2.520 |
| Volume | 1,373,931 |
| Market Cap | 2.58M |
| PE Ratio (TTM) | -0.1071 |
| EPS (TTM) | -1.1 |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | 354,355 |
Chart
About Oragenics Inc. Common Stock (OGEN)
Oragenics Inc is a biotechnology company focused on the development of innovative solutions for infectious diseases and oral health. The company is primarily engaged in creating novel antibiotics and therapeutics, particularly against multi-drug resistant pathogens, as well as products aimed at enhancing oral health through advanced microbial therapies. Oragenics leverages its proprietary technologies and research capabilities to address significant medical needs, with a mission to improve patient outcomes and combat rising antibiotic resistance through targeted and effective treatment options. Read More
News & Press Releases
Let's have a look at what is happening on the US markets one hour before the close of the markets on Wednesday. Below you can find the top gainers and losers in today's session.
Via Chartmill · May 28, 2025
Via Benzinga · May 28, 2025
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
Via Chartmill · May 28, 2025
The market is buzzing with gapping stocks on Wednesday. Let's uncover which stocks are experiencing notable gaps during today's session.
Via Chartmill · May 28, 2025
BioMedNewsBreaks — Oragenics Inc. (NYSE American: OGEN) Sets 1-for-30 Reverse Stock Split Effective June 3
Oragenics (NYSE American: OGEN) announced that its board has approved a 1-for-30 reverse stock split of its common shares, effective June 3, 2025. The move consolidates every 30 shares into one and aims to boost the company’s share price and appeal to long-term investors. Shares will begin trading on a split-adjusted basis under the existing symbol “OGEN” with a new CUSIP number. CEO Janet Huffman stated the action aligns with Oragenics’ strategy to enhance its capital markets profile while advancing treatments for brain-related health conditions.
Via Investor Brand Network · May 28, 2025
InvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Secures Australian Approval to Launch Phase II Concussion Trial
Oragenics (NYSE American: OGEN) a biotechnology company developing intranasal therapies for brain-related disorders, announced it has received approval from Australia’s Human Research Ethics Committee (“HREC”) to begin a Phase II clinical trial of ONP-002, its proprietary neuroprotective therapy for mild traumatic brain injury (mTBI), or concussion. The clearance enables the company to initiate patient enrollment as early as Q2 2025 at Level 1 trauma emergency departments, where concussed patients are often treated. ONP-002, a non-invasive intranasal formulation, has demonstrated safety in Phase I and efficacy in preclinical models by reducing inflammation, oxidative stress and brain swelling. CEO Janet Huffman said the approval marks a key step toward expanding the ONP-002 program internationally, with enrollment sites also under consideration in New Zealand.
Via Investor Brand Network · May 13, 2025
InvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) to Host May 20 Webinar on Concussion Drug Program ONP-002
Oragenics (NYSE American: OGEN) will host a management update webinar on Tuesday, May 20, 2025, at 4:00 p.m. ET to discuss the unmet medical need in concussion treatment and highlight its lead candidate, ONP-002. The intranasal therapy is currently in a Phase IIa trial for mild traumatic brain injury and has shown promising preclinical results in reducing brain inflammation and swelling. Presenters will include CEO Janet Huffman, CMO Dr. James Kelly, and Chief Clinical Officer Dr. Frank Peacock, a national emergency medicine expert.
Via Investor Brand Network · May 12, 2025
Via Benzinga · May 5, 2025
As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.
Via Chartmill · May 5, 2025
Oragenics (NYSE American: OGEN) announced the submission of its Phase II clinical trial protocol to New Zealand’s Health and Disability Ethics Committee, advancing plans to evaluate ONP-002, its intranasal neurosteroid therapy for mild traumatic brain injury. If approved, patient enrollment will begin at Christchurch Hospital, one of Australasia’s busiest emergency care centers. The company aims to expand its clinical reach across Australia and New Zealand, addressing a major unmet need for concussion treatment.
Via Investor Brand Network · April 9, 2025
Oragenics (NYSE American: OGEN), a biotechnology company developing intranasal therapies for brain-related disorders, announced that Chief Medical Officer Dr. James Kelly participated in a panel at the 3rd Nasal Formulation & Delivery Summit held April 1–3 in Boston. Dr. Kelly discussed advancements in intranasal drug delivery, its benefits for neurological treatment, and the company’s progress with ONP-002, a neurosteroid aimed at improving concussion outcomes through rapid, targeted brain delivery.
Via Investor Brand Network · April 8, 2025
After the closing bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.
Via Chartmill · April 7, 2025
Via Benzinga · April 7, 2025
Via Benzinga · April 2, 2025
InvestorNewsBreaks – Oragenics Inc. Highlights Q1 Milestones and Prepares for Concussion Drug Trial
Oragenics (NYSE American: OGEN) reported significant strategic progress in Q1 2025 as it advances ONP-002, its intranasal concussion therapy, toward clinical Phase IIa trials in Australia. The company secured a partnership with BRAINBox Solutions to integrate diagnostic biomarkers with its treatment platform and raised approximately $5 million through a mix of equity and non-dilutive debt. Oragenics also finalized regulatory submissions and drug production, with first patient enrollment expected in Q2. With no FDA-approved treatments for concussion, ONP-002 is positioned as a potential first-in-class therapy addressing a major unmet need.
Via Investor Brand Network · March 27, 2025
InvestorNewsBreaks – Oragenics Inc. Files 2024 Annual Report, Addresses Going Concern Status
Oragenics (NYSE American: OGEN) announced the filing of its Annual Report on Form 10-K for the year ended Dec. 31, 2024, with the U.S. Securities and Exchange Commission on March 14, 2025. The company’s audited financial statements received an unqualified audit opinion, though an explanatory paragraph raised concerns about its ability to continue as a going concern. Oragenics remains focused on advancing its pipeline of treatments for concussion and brain-related health conditions while pursuing strategic opportunities to ensure long-term growth. Further details are available in Footnote 1 of the financial statements.
Via Investor Brand Network · March 19, 2025
BioMedNewsBreaks — Oragenics Inc. Advances Concussion Treatment with Phase II Trial Preparation
Oragenics (NYSE American: OGEN), a biotechnology company developing treatments for brain-related health conditions, has submitted its Investigator’s Brochure in preparation for a Phase II clinical trial of ONP-002 in Australia. ONP-002, a novel intranasal neurosteroid, has demonstrated potential in reducing inflammation, oxidative stress, and brain swelling in preclinical studies. With a prior Phase I trial confirming safety and tolerability, the upcoming study aims to assess feasibility and proof-of-concept in mild traumatic brain injury (mTBI) patients. Regulatory approvals are expected in the coming weeks, bringing Oragenics closer to initiating the trial.
Via Investor Brand Network · March 6, 2025
BioMedNewsBreaks — Oragenics Inc. (NYSE American: OGEN) Highlights Concussion Treatment Advances at Emergencies in Medicine Conference
Oragenics (NYSE American: OGEN) announced its participation at the Emergencies in Medicine Conference, where Chief Medical Officer Dr. James Kelly presented on advancements in concussion treatment. His session focused on Oragenics’ “Trigger-to-Treat” program and the development of ONP-002, an intranasal neurosteroid designed for acute concussion care. The presentation also highlighted the integration of BRAINBox Solutions’ multi-marker diagnostic platform in clinical trials to enhance concussion detection and prognosis. Oragenics aims to establish a new standard for early intervention and precise treatment strategies, contributing to improved patient outcomes in concussion management.
Via Investor Brand Network · February 25, 2025
BioMedNewsBreaks — Oragenics Inc. (NYSE American: OGEN) Appoints Chief Medical Officer to Medical Board of The Leigh Steinberg Foundation
Oragenics (NYSE American: OGEN), a biotechnology company advancing innovative treatments for concussion and brain-related health conditions, announced that its Chief Medical Officer Dr James Kelly has been appointed to the Medical Board of The Leigh Steinberg Foundation for Concussion, Traumatic Brain Injury and Brain Health. The appointment reflects Dr Kelly’s pioneering work, including his previous leadership at the National Intrepid Center of Excellence at Walter Reed National Military Medical Center, and reinforces the foundation’s mission to support research, raise awareness and drive actionable solutions for brain injury care. Janet Huffman, Interim Chief Executive Officer and Chief Financial Officer of Oragenics, noted the move bolsters the company’s commitment to developing its novel intranasal treatment for concussion, ONP-002, while Leigh Steinberg welcomed Dr Kelly’s expertise in transforming concussion treatment. Dr Kelly said he is honored to join the Medical Board and dedicated to advancing innovative treatment options to improve patient outcomes.
Via Investor Brand Network · February 24, 2025
InvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Partners With BRAINBox Solutions to Advance Concussion Care
Oragenics (NYSE American: OGEN) announced a strategic collaboration with BRAINBox Solutions to develop an integrated diagnostic and treatment platform for mild traumatic brain injury (mTBI). The partnership will combine BRAINBox’s AI-driven diagnostic technology with Oragenics’ intranasal therapeutic candidate, ONP-002, aimed at mitigating brain injury effects and promoting recovery. The initiative seeks to establish a seamless “trigger-to-treat” system, enhancing early diagnosis and personalized treatment. With over 5 million concussions occurring annually in the U.S., the companies aim to set a new standard in TBI management.
Via Investor Brand Network · February 11, 2025
Let's dive into the action on the US markets on Wednesday. Here are the most active stocks that are driving the market today.
Via Chartmill · February 5, 2025
Here are the top movers in Wednesday's session, showcasing the stocks with significant price changes.
Via Chartmill · February 5, 2025
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Wednesday.
Via Chartmill · February 5, 2025
Wondering what's happening in Wednesday's pre-market session? Find an overview in this article.
Via Chartmill · February 5, 2025
